This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
Operator
Good day and welcome to IAM Cannabis' fourth quarter and fiscal year 2021 earnings conference call. Today's conference call is being recorded. At this time, I would like to turn the conference over to Maya Lustig, Director of Investor and Public Relations.
Maya Lustig
Thank you, Operator. Joining me today are IAM Cannabis Chief Executive Officer Oren Schuster, and Chief Financial Officer Shai Shemesh. Earlier today, I Am Cannabis released financial results for the fourth quarter and full year 2021. The earnings release that accompanies this call is available on the investor relations section of our website at investors.iamcannabis.com. Today's call will include estimates and other forward-looking information, including statements concerning future revenues, results from operations, financial positions, markets, economic conditions, product releases, partnerships, and any other statements that may be constructed as a prediction of future performance. This information may involve known and unknown risks uncertainties, and other factors which may cause actual results to differ materially from those expressed or implied by such statements. Factors that could cause or contribute to such differences are described in detail in the company's most recent filings available on SIDAR at www.sidar.com. Furthermore, certain non-IFRS measures will be referred to during this call. The company believes that the presentation of this non-IFRS information provides useful supplementary data concerning the company's ongoing operation and is provided for informational purposes only. Any estimates or forward-looking information provided are accurate only as of the date of this call and the company undertakes no obligation to publicly update any forward-looking information or supply new information regarding the circumstances after the date of this call. Please also note that all references on this call reflect currency in Canadian dollars. With that, it is my pleasure to turn the call over to Oren Schuster, CEO of I Am Cannabis. Oren, please go ahead.
Oren Schuster
Thank you, Maya. Hello, everyone, and thank you for joining us for our first earning call. In just over two years, since I Am Cannabis became a public company, we have made a significant amount of headway in positioning our enterprise to become a leading producer of premium cannabis globally. In 2019, we successfully went public on the Canadian Securities Exchange. And in March of 2021, we became the first Israeli cannabis operator to list on the NASDAQ. Over three rounds of financing, we successfully raised approximately $70 million, which was prudently deployed into the business. In exchange for this capital, we have grown our annual revenue base nearly 10 times over the last three years, from just over $5 million in 2019 to a record of over $54 million in 2021. representing revenue growth of over 240% in fiscal 2021. Most notably, we grew revenue by 309% year-over-year to over 20 million in the fourth quarter and exited the year at an approximate 80 million revenue run rate, which showcases our accelerated growth. The strategic steps we have taken to capitalize on the evolving global regulatory landscape and calculated approach towards building our global supply chain framework have today allowed us to become one of the leading distributors of medical cannabis in Israel with an established presence in the Canadian and German cannabis market. Ultimately, we see a pathway to capturing over 30% market share of the premium cannabis industry in Israel and over 10% share of the EU market within five years. But going further, for those of you who may be new to our story. I would like to first provide an overview of I Am Cannabis and the vision that our team has been working towards since inception. Afterwards, I will provide some detail on our market segments that collectively position us for long-term growth, followed by review of our financial results before we open the call up for your questions. I Am Cannabis, or IMC, is a leading global provider of premium cannabis for the medical and recreational markets and the only multi-country operator with the footprint in Israel, Canada, and Germany, the three largest markets in which cannabis is legal at the federal level. According to New Frontier Data, one of the cannabis industry's leading data and analytics firm, global sales of legalized cannabis in 2020 were almost 24 billion USD. Due to the ongoing liberalization and commercialization of cannabis, this figure is expected to over double to 51 billion USD by 2025, just under three years from today. This emerging global economy is primed with opportunities, but to capitalize on them will require the navigation of complex regulations, established infrastructure, and deep understanding of evolving market trends. all of which serve as the basis for IMC's success. Our vision is, and always has been, to become one of the world's largest premium cannabis producers, leveraging our well-respected brand with super premium products and a loyal customer base has allowed us to become a market leader in a relatively short amount of time. And while other operators, may have aspiration to reach the dominant scale IMC is working towards, we are uniquely positioned to continue growth with the highest quality products in the market, which is a key differentiator that will enable us to continue growing sustainably. Our accumulation of knowledge and operating expertise dates back over a decade and informs every strategic and operational decision that we make. In 2010, I founded one of the eight medical cannabis producers that were initially licensed by the Israeli authorities. This entity, which becomes the initial cultivator and processor for IMC, provided the foundation of our operating platform. As regulatory reforms continue to develop, we replicated our success internationally. Fast forward into today, we have completed seven strategic acquisitions and built a world-class network of pharmacies. Not only are our operations vertically integrated, but we have ample premium cultivation capacity, sought-after brands, and top-tier infrastructure with extensive distribution reach, all of which have provided an early-mover advantage that positions IMC for significant leadership opportunity as the market evolves. Let me go into some more detail on some of the most important steps we have taken. In 2019, we acquired Logistics Hub in Germany that is EU GMP certified, making IMC one of the few companies that can procure bulk products, repackage it in Germany, and sell it directly to pharmacies, leveraging the facility's 13-year track record of successful distribution. We quickly developed IMC's brand presence in Germany and commenced sales into Europe in the fourth quarter of 2020. Subsequently, we made key upgrades to this facility with state-of-the-art technology and completed an expansion that doubled IMC's footprint in Germany to approximately 8,000 square feet. Germany is an important market as we prepare for more significant entry to the broader European market. And today, IMC products are available at all relevant pharmacies that sell cannabis in Germany. We also completed the landmark acquisition of Tricom in March 2021, which provided us with premium indoor cultivation facility that increased our capacity by over 15,000 pounds to serve the high demand for premium cannabis across our market. We further secured our foothold in the Canadian market through our acquisition of MYM, which provided cost-to-cost distribution in Canada, while accelerating our entry strategy into new markets and bolster our export capabilities to serve our existing Israeli and German operations. In Israel, where patients are required to obtain medical cannabis through pharmacies, we closed four key acquisitions earlier this month. These additions will have consolidated four of Israel's leading pharmacies under one ownership, immediately making IMC one of the leading retail medical cannabis providers in the country. Importantly, we now operate Israel's largest online pharmacy business, which supports the expansion of modern patient base as e-commerce is widely adopted as the preferred retail medium. Leading the modernization of the industry strengthens our direct links to consumers by allowing IMC to manage patient relationships end-to-end and bolsters our in-house data for use across all platforms. Finally, IMC also secured an IMC GDP License Trade Center, which we will leverage to increase our purchasing power with suppliers and expand our range of products. This includes highly recognized brands, some of which we now have exclusive agreements to import. We now have the resources needed to ensure the efficient movement of supplies across our platform. effectively serve some of the most rapidly growing consumer segments in Israel, and ultimately drive increased satisfaction and consumption of our products. We have strategically entered each of the markets we are operating in, not only due to the size of the markets, but due to the holistic nature of our platform and taking each segment into account. As mentioned earlier, IMC's story began in Israel, where we have over a decade of experience in growing and selling premium cannabis. The study I referred earlier states Israel imported more cannabis in 2020 than any other country, while also having the world's highest cannabis usage rate per capita, outpacing the United States by nearly 10%. Israel's long history of cannabis medical research has led to the country becoming a flourishing research and development hub, which is naturally aligned with IMC's core values. Our commitment to quality is what originally led the primary focus toward premium sex. Our vertically integrated operations have enabled IMC to succeed in countries' strangely controlled regulatory environments. while allowing us to stay ahead of trends and generate operating efficiency. In the near term, we believe that Israel will continue to be the highest growth segment for IMC, as we realize the benefits from our expanded global platform. Over the longer term, however, we expect to leverage our successful and reputation in Israel into Germany, which presents an even more substantial opportunity Like Israel, Germany has a very active pharmaceutical market, and as a result, has a science-based cannabis market supported by extensive medical studies. Cannabis is distributed through pharmacies to approximately 100,000 patients in the country, and the German government employs a strong reimbursement program which supports a high pricing structure. As you might expect, This creates an environment that caters to premium products, thereby giving a distinct advantage to operators who are able to constantly meet the levels of associated standards. Also similar to Israel, Germany is a heavily regulated environment that requires a significant level of expertise to navigate. Our EU GNP certification is an incredible asset in this regard and further position us to be a market leader in this sector. Germany's economic success with its medical program, as in our opinion, made the legalization of adult-use recreational cannabis becoming a top government priority. Due to its position as the economic and logistical hub for the EU, Germany could potentially provide one of the greatest growth catalysts in the cannabis market. And we believe we are better positioned to than anyone to capture this market share. As you may know, Canada was the first G7 country to federally legalize recreational cannabis and has the highest production capacity of premium products outside of the U.S. Our strategy of developing a Canadian presence was rooted in the ability to have a world-class manufacturing hub to serve all of our addressable markets that are high importers of premium products. Based on recent sales figures, IMC's brands are popular with Canadian consumers and are leading the premium market. Notably, our Highland & Wagner's brands are ranked as number one and number six respectively, in Ontario, which generally reflects consumer preferences across Canada being its largest market. We expect our indoor cultivation facilities in Canada to be operating at full capacity to meet the elevated demand for our products and brands on a global scale. The synergies created by our specific operating footprint can be summarized in three points. We are leveraging our regulatory know-how and extensive database of medical patient data and insights from Israel to inform our operations in Germany and in Canada. Our indoor cultivation facility in Canada will support the export of premium products to markets like Israel and Germany, in which consumers are amenable to paying a higher price for premium products. Our Germany-certified facility serves as the pan-European distribution hub. As we prepare for future recreational demand in the EU, we stand to benefit from our unique infrastructure and early mover advantage. Again, only two players in Germany can make this claim. With that, I would like to turn the call over to our Chief Financial Officer, Shai Shemesh, who will review our fourth quarter and fiscal year 2021 financial results. Shai?
Maya
Thank you, Oren. As mentioned, IMC is operating from a position of financial strength. Since inception, the capital we've raised has been strategically allocated across our business and created tremendous value in our business, most notably by looking at our compounded annual revenue growth rate of approximately 120% since 2018. I will now provide an overview of our fourth quarter and fiscal year 2021 financial and operational results. Revenues increased 309% to $20 million in the fourth quarter of 2021, compared to $4.9 million in the fourth quarter of 2020. Revenues increased 242% to $54.3 million in 2021, compared to $15.9 million in 2020. The increase in revenue is primarily attributed to an increase in the quantity of medical and recreational cannabis sold. Gross profit before fail value adjustment was $3.8 million in the fourth quarter of 2021 compared to $2.8 million in the fourth quarter of 2020. Gross profit before fair value adjustment was $11.9 million in 2021 compared to $8.8 million in 2020. Gross profit was temporarily impacted in the fourth quarter of 2021 by COVID-19 restrictions in Canada and Israel, which delayed third-party manufacturing, disruptive labor, and supply chains. Total operating expenses were $16 million in the fourth quarter of 2021 compared to $6.9 million in the fourth quarter of 2020. Total operating expenses were $48.7 million in 2021 compared to $18.7 million in 2020. The increase in total operating expenses includes costs associated with seven acquisitions and expenses related to capital market activities. Net loss was $12.5 million in the fourth quarter of 2021 compared to a net loss of $20 million in the fourth quarter of 2020. Net loss was $18.5 million in 2021, compared to a net loss of $28.7 million in 2020. Basic and diluted loss per share in the fourth quarter of 2021 of 19 cents, compared to basic and diluted loss per share of 13 cents in the fourth quarter of 2020. Basic and diluted loss per share in 2021 was 31 cents and 66 cents respectively compared to basic and diluted loss per share of 74 cents in 2020. Non-IFRS adjusted EBITDA was negative $8.3 million in the fourth quarter of 2021 compared to an adjusted EBITDA loss of $2.4 million in the fourth quarter of 2020. Adjusted EBITDA was negative $22 million in 2021 compared to a negative $4.9 million in 2020. Excluding acquisition costs of $4.3 million in 2021, adjusted EBITDA would have been negative $7.7 million in 2021, compared to negative $4.9 million in 2020. And finally, cash and cash equivalent total $13.9 million at December 31, 2021, compared to $8.9 million at December 31, 2020. While we continue to take an opportunistic approach to our capital allocation strategy, we currently do not have any new acquisition plans. More importantly, we have already began to realize the synergies of our consolidated operations. As a result, in the first quarter of 2022, we expect revenues to accelerate on a year-over-year basis while continuing to grow sequentially. We are also pleased to announce that we are rapidly approaching positive cash flow and positive adjusted EBITDA, which we expect to achieve in the second quarter of 2022. I would like now to turn the call back to Owen for closing remarks. Owen?
Oren Schuster
Thank you, Shadi. In 2022, we are launching our top Canadian brands in Israel and Germany, while continuing to take the steps for alignment with ongoing regulatory reforms. As we look forward, our strategy is to unify our brands under the same high standards that we have always prioritized. We believe this will ultimately result in IMC becoming a leading international consumer packaged goods company, serving the cannabis industry. not dissimilar to the brands you know and love. Worth noting, the steps we've taken have positioned IMC to become one of the largest players in the European premium cannabis market. Given this positioning, we estimate that in five years, IMC could have over 30% share of the market in Israel and over 10% share of the EU premium cannabis market if we execute well against our strategic growth plan. Of course, this assumes that we do not encounter significant unforeseen events and that the regulatory environment in our key markets will continue to evolve as we expect. While there are several developments that need to occur in order to achieve vision, we feel our experienced team, regulatory expertise, and unique supply chain infrastructure have positioned us to excel in this dynamic environment. With that, I hand the call over to the operator to begin our question and answer session. Operator?
Operator
Thank you. We will now begin the question and answer session. To join the question queue, you may press star then one on your telephone keypad. You will hear a tone acknowledging your request. If you're using a speakerphone, please pick up your handset before pressing any key. to withdraw your question. Please press start then two. We will pause for a moment as callers join the queue. Our first question is from Aaron Gray with Owings Global Partners. Please go ahead.
Aaron Gray
Hi, good morning, and thank you for the questions, and congrats on the first earnings on the quarter. So first question for me, Strong momentum in Canada for you guys' premium brands. As you guys now look potentially, you know, export some of those to Israel and otherwise, you know, how do you guys think about allocation of product to both maintain momentum in Canada while also capitalizing on the opportunities you have internationally in Israel and otherwise? So just any comment in terms of how you think about, you know, prioritizing between the two would be very helpful. Thank you.
Oren Schuster
Hi, it's Oren. Thank you for the question. It's a very good question. So in Canada, what we're doing is building actually our distribution center for Israel and for Germany and for the Canadian market. And the allocation from Canada is being done according to the different brands. And what we are trying to do is to optimize the allocation according to the brand, to the market, where we can get the highest margins, while taking into consideration not to lose market share in each of the markets. To do so, we also will do more purchasing if needed from outsourced. But all the metrics will be held in Canada with this optimization.
Aaron Gray
Okay, thank you. That's helpful color there. And second question for me, Shai, I think you mentioned profitability to Q2022. Could you maybe break down, you know, a pathway of how you guys look to get there between gross margin and SG&A? You know, this quarter, the $8 million EBITDA loss, so a pretty hefty improvement over the next two quarters, so just to help the pathway to that between gross margin and SG&A, that'd be helpful. Thank you.
Maya
Yes. Hi, Aaron. Well, first of all, as you well know, 2021 was a very hectic year for us with all the acquisition, the NASDAQ listing, and the financing run that we did. So this basically, we had lots of transaction costs related to that and all other costs related to the other items. When you look at our balance sheet, you will see that we have nice inventory levels that are going to be utilized during 2022. Apart from full consolidation of all the subsidiaries that now we are starting consolidating from day one, and not partially, the increase in revenues due to the synergy and the integration and what Oren mentioned before, as well as the reduction of the one-time cost that we are not expecting to have at the moment. We believe that we will reach a positive adjusted EBITDA at Q2, as we said, and gross margins that were relatively low in Q4 are estimated to increase as well.
Aaron Gray
Okay, thank you. Anyway, could this help to quantify, you know, how much of those one-time impacts were that were included in that EBITDA number, just so we can get a better run rate on the go forward there for SG&A? Thank you.
Maya
Yeah. I think it was inside the press release that was sent, that was released. First of all, we had acquisition costs of $4.3 million in 2021. We had another $1.3 million that related to our NASDAQ listing. And in general, we paid around $20 in cash. I'm switching to the cash. In cash, we paid more than $20 million for all – $22 million for all the acquisition, NASDAQ listing, everything involved. So does this answer your question?
Aaron Gray
Okay, yeah. Yeah, I just wanted to make sure. I thought those had been shipped out of the adjusted EBITDA. But I'll go ahead and ask some more questions on the back end, and I'll jump back into the queue for now. Thank you very much for the details. Thank you.
Operator
Our next question is from Scott Fortin with Rouse Capital Partners. Please go ahead.
Scott Fortin
Good morning or afternoon, where you are, and thanks for taking the questions. Real quick, you've done a nice job of acquiring. You've broadened your ecosystem and sales channel in Israel to become vertically and more vertically integrated with pharmacies and online business platforms. you know, Panaxia and such. Can you provide a little color on the synergies with some products, including Wagner's and others, selling it through retail, delivery, and distribution to drive growth and margin expansion here? Kind of what type of margins from those margins and EBITDA side are you kind of expected to reach once you get this fully integrated into your systems into Israel going forward? And then just a quick update on kind of the continuing patient growth that's going on in Israel would be helpful.
Oren Schuster
Okay. So, hi, it's Oren. First of all, regarding the synergies and what we see is definitely that the strategy is working and we're starting to see the benefits of the synergy. It's starting with the production in Canada, and we've started to get shipments from our own production facility as well as from other partners in Canada. Also in Israel, we started the integration of, first of all, the home delivery distribution centers that we acquired It starts from call centers, centralized delivery centers, and so on. We are starting to recognize many of the efficiencies over there. Also, what we are doing is we are centralizing the purchasing, which gives us higher margins for the pharmacies. All of that and the fact that we are vertically integrated and selling our own products in our own pharmacies in Israel, for our own products, the margins are well more than 50%. With the other products, it's a bit lower. So it depends on which pharmacy you are in. chain of the company we are talking about. But if we're talking about the vertically integrated parts, it can be 70% even. And if we're speaking about pharmacies, for example, it can be even 25% to 30%. We are working more and more to sell our own products to get higher gross margins. The market in Israel is continuing to grow. We've seen this year that the growth pace is lower than it was last year, mainly because of regulatory issues that has to be more clear. On the other hand, in Israel, we see that there is a process of legalization of medical cannabis have started, so I think that it will be more regularized and we will see significant increase in the Israeli market. I'm not sure that I answered all the questions, so we can do it.
Scott Fortin
No, that's perfect. You provided a lot of color and detail on that. And then real quick, kind of shifting back to Canada here, can you provide a production capacity update from your Canadian facilities, kind of the yield improvement that you've seen and the on-take for dry flour from your exports? and the supply for the Canadian market. You mentioned how to balance that out, but just kind of give a sense for your own production capability and opportunity in Canada. And then are you looking to add potentially more opportunities to add production to serve the premium Canadian market and their national markets going forward here? How are you looking at your production footprint to serve the high-value markets going forward?
Oren Schuster
So our production capacity is nearly 15,000 pounds annually in our main production facility in Canada. I hope that we will be able to extend that. Anyway, we are doing also B2B, especially for the Israeli market and the German market, that is centralized through Canada. So in the future, we're going to also continue with B2B purchases because there is overcapacity today in Canada and for us it's good. And definitely in the future, if we will need more capacity, we will extend the facility.
Scott Fortin
I appreciate the call. I will jump back in the queue. Thanks. Okay. Thank you.
Operator
Once again, if you have a question, please press star then one on your telephone. Our next question is from Adam Alsberger with BMO. Please go ahead.
Adam Alsberger
Good morning. Good morning, guys. And just wanted to congratulate you on an unbelievably busy year battling COVID challenges and all of the transactions that the team has done. I know that they've worked insane hours and just want to congratulate you guys and obviously the entire IMC team, especially it's quite the accomplishment to exit the year at an $80 million annualized revenue run rate. And I know that we got nowhere to go but up from here. Shai, it was very good to hear as well, you know, roughly what the total costs were that were incurred during 2021. to transact on all the various acquisitions and on the NASDAQ listing. Obviously, with the team focused moving forward on getting the overall machine humming that those one-time costs should come down and now the focus is on the bottom line and running a smooth operation. with no new acquisition plans currently in the pipeline. So very excited at how 2022 and the years ahead are looking. I do have a couple questions for you guys. First off, is there any insight that you have into any updated political momentum changes towards recreational legalization in Israel?
Oren Schuster
So Israel, now there is a work on a new law for medical cannabis. Israel officially decriminalized cannabis lately in the last month or so. So I think that in general the approach is very positive towards cannabis. I believe that first of all we will see the legalization of medical cannabis that will happen very quickly. And after that, the process of legalization will be much easier once medical cannabis will be legalized. So it's very difficult for me now to give any estimation regarding timelines about legalization. We need more visibility that probably we'll have during this year.
Adam Alsberger
Okay, great. Can you maybe give a little bit more color around Germany and how the progress is going there and the status of the ease or restrictiveness, I'm not really sure, of the availability to import product from your Canadian operations and or Israeli operations?
Oren Schuster
So in Germany, as we all know, have started to announce officially that they are going to legalization. First of all, we feel it and we see that in Germany the discussion about cannabis is much more open than it was in the past and it's starting to become something very in the main street, unlike it was before. And it's a very good sign. And also what we see in Germany is a significant increase in the number of patients that are self-payers, are not going through the reimbursement program of the insurance. So we see definitely increase in that segment, which is very similar to the recreational segment which is aligned very well with our strategy of bringing premium products from Canada. We are now selling products that we are importing from Canada, not from our own facility, but we are working extensively on building the pathway to send our own products to Germany. and I believe that later this year we will start to manage that from our own facility, our own operation in Canada. We started to get product from Canada to Israel from our own facility, so the process is progressing and moving, and I'm very optimistic about that.
Adam Alsberger
Great. Do you guys have any comparative data that shows how IMC is performing versus your competitors in Israel specifically. I know that you mentioned that you have a goal to obtain 30% of market share for premium product in Israel. Can you maybe give everyone an idea of how IMC is doing versus competitors?
Oren Schuster
So the Israeli market, in the Israeli market, we have a few kinds of players in the medical cannabis. Some of them have the GMP facilities, some growing, some have retail. IMC is vertically integrated. We are also growing and also have the retail chain and the direct supply. Today, we are one of the top players. I think that if we are speaking about public companies, probably we are today number two, I think, in numbers in Israel. And I think that 2022 will be way, way better for IMC in Israel than 2021 was.
Adam Alsberger
Okay, fantastic. And then just if you could touch on Germany slash the EU markets, because there have been a few companies, I believe, like Akira Leaf and Atil Ray that have touched on their aspirations to generate, I believe, don't quote me on this, but a billion dollars plus annualized within a certain time period. that specifically relate to the EU. Any comments you could make around IMC's market share and progress in Germany that you haven't already expanded on?
Oren Schuster
What we have done until now in Germany, we have built the infrastructure and the preparation for the market expansion. We have done that with our EUGMP facility in Germany. We have built a significant logistics center in Germany to be able to get a product to store it and to distribute it to the German market and also to the rest of the EU market directly from our logistics center. And now we are making sure that we will have enough product and premium product to support all the infrastructure that we build and all the demand that will be generated in Germany. I think that we are putting all the foundations for this market that everybody is talking about. I do wish the competitors those numbers because it means that the market is going to be huge and we will have healthy competition.
Adam Alsberger
Excellent answer. Thank you. That's all I have, and again, thanks very much to the entire team for all their hard work.
Oren Schuster
Thank you very much, Adam.
Operator
This concludes the question and answer session. I would like to turn the conference back over to Oren Schuster for any closing remarks.
Oren Schuster
Thank you, Operator, and thank you all for joining us for our call today. Please continue to track our progress as we continue to execute on our growth strategy. And I look forward to speaking with you in the coming quarters.
Operator
This concludes today's conference call. You may disconnect your lines. Thank you for participating and have a pleasant day.
Disclaimer